NASDAQ:EPIX
ESSA Pharma Inc. Stock News
$6.43
+0.290 (+4.72%)
At Close: Apr 30, 2024
ESSA Pharma Provides Corporate Update and Reports Financial Results for Fiscal Second Quarter Ended March 31, 2021
07:01am, Thursday, 06'th May 2021
- Presented promising preliminary pharmacokinetic and clinical data on EPI-7386 in metastatic castration-resistant prostate cancer at 2021 AACR - Raised approximately $150 million in a public offeri
ESSA Pharma to Present at the Bloom Burton & Co. Healthcare Investor Conference
07:00am, Wednesday, 14'th Apr 2021
HOUSTON, Texas and VANCOUVER, Canada, April 14, 2021 /PRNewswire/ - ESSA Pharma Inc. ("ESSA" or the "Company") (Nasdaq: EPIX), a clinical-stage pharmaceutical company focused on developing novel ther
HOUSTON, Texas and VANCOUVER, Canada, April 10, 2021 /PRNewswire/ -- ESSA Pharma Inc. ("ESSA" or the "Company") (Nasdaq: EPIX), a clinical-stage pharmaceutical company focused on developing novel t
ESSA Announces Change to its Board of Directors
04:05pm, Friday, 26'th Mar 2021
HOUSTON, Texas and VANCOUVER, BC, March 26, 2021 /PRNewswire/ - ESSA Pharma Inc. ("ESSA" or the "Company") (Nasdaq: EPIX), a clinical-stage pharmaceutical company focused on developing novel therapie
ESSA Pharma Inc. Reports Results of Annual General and Special Meeting of Shareholders
06:33pm, Thursday, 25'th Feb 2021
HOUSTON and VANCOUVER, BC, Feb. 25, 2021 /PRNewswire/ - ESSA Pharma Inc. ("ESSA" or the "Company") (NASDAQ: EPIX) (TSX-V: EPI), a clinical stage pharmaceutical company focused on developing novel ther
ESSA Pharma Announces Closing of $130 Million Public Offering of Common Stock
11:48am, Monday, 22'nd Feb 2021
VANCOUVER, BC and HOUSTON, Feb. 22, 2021 /PRNewswire/ - ESSA Pharma Inc. ("ESSA", or the "Company") (Nasdaq: EPIX), a clinical-stage pharmaceutical company focused on developing novel therapies for th
ESSA Pharma Announces Pricing of Public Offering of Common Shares
10:47pm, Wednesday, 17'th Feb 2021
VANCOUVER, BC and HOUSTON, Feb. 17, 2021 /PRNewswire/ - ESSA Pharma Inc. ("ESSA", or the "Company") (Nasdaq: EPIX), a clinical-stage pharmaceutical company focused on developing novel therapies for th
VANCOUVER, BC and HOUSTON, Feb. 11, 2021 /PRNewswire/ - ESSA Pharma Inc. ("ESSA", or the "Company") (NASDAQ: EPIX), a clinical-stage pharmaceutical company focused on developing novel therapies for th
ESSA Pharma Provides Corporate Update and Reports Financial Results for Fiscal Fourth Quarter and Year Ended September 30, 2020
05:01pm, Tuesday, 15'th Dec 2020
VANCOUVER and HOUSTON, Dec. 15, 2020 /PRNewswire/ - ESSA Pharma Inc. ("ESSA", or the "Company") (NASDAQ: EPIX), a clinical-stage pharmaceutical company focused on developing novel therapies for the tr
ESSA Pharma Inc. Announces Delisting from the TSX-V
05:01pm, Monday, 26'th Oct 2020
HOUSTON and VANCOUVER, BC, Oct. 26, 2020 /PRNewswire/ - ESSA Pharma Inc. ("ESSA" or the "Company") (TSX-V: EPI) (NASDAQ: EPIX), a clinical stage pharmaceutical company focused on developing novel ther
ESSA's Novel Prostate Cancer Treatment In Clinical Trial: Pfizer Is New Lead Investor
11:48am, Wednesday, 19'th Aug 2020
ESSA's EPI-7386 novel approach to treat prostate cancer by targeting the N-terminal domain androgen receptor inhibitor is now in Phase 1 trials.
EPIX: $45 Million Financing Includes Investment from Pfizer; Dosing Begins in Phase 1 Trial of EPI-7386…
01:22pm, Wednesday, 12'th Aug 2020
By David Bautz, PhD NASDAQ:EPIX READ THE FULL EPIX RESEARCH REPORT Business Update Additional Preclinical Data Presented at AACR 2020 On June 22, 2020, ESSA Pharma Inc. (EPIX) announced new preclinica
Franklin Berger Is The Independent Director of ESSA Pharma Inc. (CVE:EPI) And They Just Picked Up 18% More Shares
10:16am, Friday, 07'th Aug 2020
Those following along with ESSA Pharma Inc. (CVE:EPI) will no doubt be intrigued by the recent purchase of shares by...
ESSA Pharma Provides Corporate Update and Reports Financial Results for Fiscal Third Quarter Ended June 30, 2020
12:00am, Friday, 07'th Aug 2020
ESSA Pharma Inc. ("ESSA", or the "Company") (NASDAQ: EPIX) (TSX-V: EPI), a clinical-stage pharmaceutical company focused on developing novel therapies for the treatment of prostate cancer, today provi
ESSA Pharma Completes Public Offering for Aggregate Gross Proceeds of US$48,990,000
02:16pm, Friday, 31'st Jul 2020
ESSA Pharma Inc. ("ESSA", or the "Company") (Nasdaq: EPIX) (TSX-V: EPI), a clinical-stage pharmaceutical company focused on developing novel therapies for the treatment of prostate cancer, today annou